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Abstract
Background: Inactivating genes in vivo is an important technique for establishing their function in
the adult nervous system. Unfortunately, conventional knockout mice may suffer from several
limitations including embryonic or perinatal lethality and the compensatory regulation of other
genes. One approach to producing conditional activation or inactivation of genes involves the use
of Cre recombinase to remove loxP-flanked segments of DNA. We have studied the effects of
delivering Cre to the hippocampus and neocortex of adult mice by injecting replication-deficient
adeno-associated virus (AAV) and lentiviral (LV) vectors into discrete regions of the forebrain.
Results: Recombinant AAV-Cre, AAV-GFP (green fluorescent protein) and LV-Cre-EGFP
(enhanced GFP) were made with the transgene controlled by the cytomegalovirus promoter.
Infecting 293T cells in vitro with AAV-Cre and LV-Cre-EGFP resulted in transduction of most cells
as shown by GFP fluorescence and Cre immunoreactivity. Injections of submicrolitre quantities of
LV-Cre-EGFP and mixtures of AAV-Cre with AAV-GFP into the neocortex and hippocampus of
adult Rosa26 reporter mice resulted in strong Cre and GFP expression in the dentate gyrus and
moderate to strong labelling in specific regions of the hippocampus and in the neocortex, mainly in
neurons. The pattern of expression of Cre and GFP obtained with AAV and LV vectors was very
similar. X-gal staining showed that Cre-mediated recombination had occurred in neurons in the
same regions of the brain, starting at 3 days post-injection. No obvious toxic effects of Cre
expression were detected even after four weeks post-injection.
Conclusion: AAV and LV vectors are capable of delivering Cre to neurons in discrete regions of
the adult mouse brain and producing recombination.
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Mice carrying conventional null mutations of genes have
been very useful in studying the roles of various molecules
in the development and functions of the nervous system.
However, the possibility of compensatory changes during
development is often raised as an explanation for the very
limited phenotypic abnormalities observed in some
knockout mice. Furthermore conventional null mutations
of genes, which have important functions during develop-
ment often show an embryonic lethal phenotype, making
experiments on adult animals impossible. The ability to
manipulate the genotype in vivo provides major opportu-
nities for studying gene function in the mammalian nerv-
ous system and for developing novel therapeutic strategies
[1,2]. A major goal for gene therapies for neurological dis-
eases and injuries is the development of methods for the
delivery of transgenes without toxic side effects. Viruses
allow efficient gene delivery, even to postmitotic cells, but
have inherent toxic effects. Several DNA viruses have been
modified in a variety of ways to produce vectors for gene
transfer with reduced toxicity [3]. In recent years, two vec-
tors in particular, recombinant adeno-associated virus
(AAV) and lentivirus (LV) have been shown to have the
potential to mediate the delivery and stable transduction
of genes to both dividing and non-dividing cells in the
nervous system, without inducing immune responses [4-
10]. These characteristics have made such vectors particu-
larly useful for transferring a gene of interest into the CNS.
Over the last few years, development of the Cre-loxP sys-
tem, which is concerned with recombination mechanisms
in the bacteriophage P1, has provided powerful technolo-
gies for the manipulation of genes. Cre is a 38 kDa recom-
binase and loxP is a Cre-specific recognition sequence
present in bacteriophage DNA, to which the recombinase
binds. This results in the excision or inversion of stretches
of DNA flanked by loxP sites, depending on the orienta-
tion of the loxP sequences [11]. This process does not
require any additional co-factors or accessory proteins
[12]. Engineering mammalian genes with loxP signal
sequences bracketing key exons or regulatory regions thus
offers opportunities for activating, inactivating or replac-
ing specific genes of interest [13-16]. However, Cre has
been reported to have toxic effects on cells in vitro and in
vivo causing a reduction in their proliferation and induc-
ing chromosomal aberrations [17-19]. Virally-delivered
Cre has been reported to cause cavity formation in adult
mouse brain [17]. A possible explanation for the toxicity
is the presence of pseudo-loxP sequences in the genomes
of mammals, yeast and Ecoli, which function as a target
for Cre [20-23].
Several strains of mice exist which have been engineered
to express Cre under the control of promoters with vari-
ous tissue specificities. These can be bred with animals
carrying loxP-flanked genes to produce gene inactivation
in different tissues. However, there are clear advantages to
being able to deliver Cre to specific groups of neurons in
adult animals. We describe here the construction of repli-
cation deficient adeno-associated virus (AAV) and lentivi-
rus (LV) vectors expressing Cre (AAV-Cre and LV-Cre-
EGFP) and the efficiency of transduction, effects on cell
survival and efficiency of recombination in Rosa26
reporter mice, 3 days and 1, 2 and 4 weeks following ster-
eotactic injections of the vectors into the neocortex and
hippocampus. Rosa26 mice carry a copy of the lacZ (β-
galactosidase) gene as a reporter for Cre activity, control-
led by the Rosa26 locus. Expression of the gene is acti-
vated by Cre-driven removal of a stop-cassette, which
consists of the neo-expression cassette followed by three
pA sequences, flanked by loxP sites [24]. We have com-
pared LV and AAV vectors because AAV vectors can only
accept short inserts (approximately 5 kb), which rules out
its using some cell type-specific promoters. Our studies
demonstrate that viral delivery of Cre can be performed
precisely and recombination can be achieved efficiently in
the mammalian nervous system without obvious toxic
effects.
Results
Viral vectors deliver Cre to a cell line
The primary objective of this part of the study was to
determine whether the LV-Cre-EGFP and AAV-Cre viruses
allow the delivery of Cre recombinase to mammalian
cells. 293T cells were infected either with LV-Cre-EGFP or
AAV-Cre viruses. Cells infected with LV-Cre-EGFP were
analysed for GFP fluorescence and immunohistochemis-
try for Cre with Cy3 conjugated secondary antibodies, 16–
48 hours after infection. Green fluorescence was detected
in the nucleus of many cells and colocalized with Cre (Fig.
1A and 1B). Cultures infected with AAV-Cre also showed
many Cre-positive cells, with the enzyme predominantly
localized in the nucleus (Fig. 1C). Uninfected cells
showed no immunoreactivity for Cre (Fig. 1D).
Virally-delivered GFP is expressed in the adult mouse brain
To verify the efficiency of gene delivery to the brain using
our viral vectors, GFP immunohistochemistry was per-
formed on coronal sections of Rosa26 mouse brain 4
weeks after injection of either a mixture of AAV-Cre and
AAV-GFP or of LV-Cre-EGFP viruses (Fig. 2). GFP was
most strongly expressed in granule cells of the dentate
gyrus, and was also strongly expressed in CA2, the termi-
nal part of the CA3 region and in scattered cells in the CA1
region of the hippocampus. Moderate to strong labelling
was found in the polymorphic layer of the dentate gyrus
(the hilus) (arrows in Fig. 2B and 2D), molecular layer of
the dentate gyrus (the suprapyramidal blade) (arrow-
heads in Fig. 2B and 2D) and the stratum lacunosum-
moleculare (arrowheads in Fig. 2A and 2C). GFP-positivePage 2 of 11
(page number not for citation purposes)
BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/4cells were also observed in subcortical white matter and
corpus callosum (arrows in Fig. 2A and 2C). Strong label-
ling of the GFP-positive fibres in the molecular layer of the
dentate gyrus was also observed (Fig. 2A,2B,2C,2D).
Most cells in mouse brain which express virally-delivered 
GFP also express Cre
In order to make sure that GFP expression was a good
marker for Cre expression in infected cells following LV-
Cre-EGFP and AAV-Cre/AAV-GFP mixture injection into
Rosa26 mice, immunofluorescence images of sections
immunoreacted for both GFP and Cre were compared
(Fig. 3). Following injection of LV or AAV vectors, the pat-
terns of Cre and GFP expression were very similar (com-
pare Fig. 3A with 3B and Fig. 3C with 3D). More cells were
Cre positive than EGFP positive, presumably because the
detection protocol for Cre was more sensitive. Following
injection of AAV-Cre/AAV-GFP mixture, most cells that
were immunoreactive for GFP were also Cre positive sug-
gesting that expression of the marker gene and Cre are
controlled by similar influences. However, the levels of
GFP and Cre varied, so that a few cells had strong GFP and
little or no Cre and a few others had strong Cre with little
or no GFP (Fig. 3E,3F, and 3G), presumably because not
(A, B) EGFP fluorescence (A) and Cre immunoreactivity (B) in HEK 293T cells infected with LV-Cre-EGFP recombinant virus in vitroFigu e 1
(A, B) EGFP fluorescence (A) and Cre immunoreactivity (B) in HEK 293T cells infected with LV-Cre-EGFP recombinant virus 
in vitro. All the cells which express EGFP also express Cre. (C, D) Immunohistochemistry for Cre, in HEK 293T cells 16 hrs 
after exposure to the AAV-Cre virus (1C) and in uninfected HEK 293T cells (1D). Cre is present in the nucleus of large num-
bers of cells infected with the virus but is absent from uninfected cells. Scale bars A and B = 25 µm, C = 50 µm, D = 100 µm.Page 3 of 11
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delivered by LV-Cre-EGFP and AAV-Cre was identified in
the nucleus of neurons.
Absence of toxic effects of gene delivery with viral vectors
No signs of cavity formation or other obvious tissue dam-
age were found in regions where GFP or Cre were detected
following injection of either AAV-Cre/AAV-GFP mixture,
or LV-Cre-EGFP viruses into mouse brain. Individual neo-
cortical neurons infected with AAV-Cre/AAV-GFP mixture
and LV-Cre viruses could be identified and they retained
their normal morphology up to 4 weeks after injection of
the vectors.
Virally-delivered Cre produces recombination in adult 
mouse brain
To show that the Cre recombinase delivered to mouse
brain was functional, the pattern of Cre-mediated recom-
bination was studied in adult Rosa26 reporter mice,
injected with either LV-Cre-EGFP or AAV-Cre/AAV-GFP
mixture. Rosa26 cells express β-galactosidase following
Cre-induced recombination. We performed β-galactosi-
dase enzyme histochemistry, 3 days and 1, 2 and 4 weeks
following the stereotactic injection of LV-Cre-EGFP and
AAV-Cre/AAV-GFP mixture into the neocortex and hip-
pocampus. These two regions were selected to establish
the potential of viruses to deliver functionally active Cre
to different cell types. β-galactosidase activity was detected
in dentate gyrus at all studied time points, but was maxi-
mal 2 and 4 weeks following viral injections into the cor-
tex and hippocampus (Figs. 4 and 5). Very strong signal
Immunohistochemistry for GFP after infusing LV-Cre-EGFP virus (A, B) and AAV-Cre/AAV-GFP mixture viruses (C, D) into the neocor ex and hippocampus of Rosa26 mouse brainFigure 2
Immunohistochemistry for GFP after infusing LV-Cre-EGFP virus (A, B) and AAV-Cre/AAV-GFP mixture viruses (C, D) into 
the neocortex and hippocampus of Rosa26 mouse brain. Very strong GFP expression is present in the molecular layer and pol-
ymorphic layer (arrows in B and D) of the dentate gyrus. GFP positive cells are present in CA1, CA2 and terminal part of the 
CA3 region of the hippocampus (A, C). Strong staining was also observed in presumptive glial cells in the subcortical white 
matter and corpus callosum (arrows in A and C). Fig. 2B and 2D are enlargements of Fig. 2A and 2C. Scale bars, A and C = 200 
µm, B and D = 100 µm.Page 4 of 11
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Double immunofluorescence for Cre and GFP using Cy3 and FITC labelled secondary antibodies respectively with single exci-
tations of 543 nm to detect Cre (A, C) or 488 nm to detect GFP (B, D). LV-Cre-EGFP virus (A-B) and AAV-Cre/AAV-GFP 
mixture viruses (C-D) were injected into the hippocampus and neocortex of Rosa26 mice 4 weeks before perfusion. The pat-
terns of expression of the two transgenes are almost identical (allowing for the slightly stronger staining obtained with the 
tyramide-enhanced Cre immunohistochemistry) irrespective of the vector used. Fig. 3E,3F, and 3G show the extent of colocal-
ization of GFP and Cre in the dentate gyrus of an AAV-Cre/AAV-GFP mixture injected Rosa26 mouse brain. In the original 
micrographs, more cells were Cre positive: 373 cells were Cre positive and 256 cells were GFP positive. However the few 
green cells in 3G show that some cells expressed GFP alone. The arrowheads and arrows in A-D indicate immunofluorescence 
in pyramidal cells of CA1 and CA2 respectively. Scale bars, A-D = 200 µm, E-G = 400 µm.Page 5 of 11
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CA2, the terminal portion of CA3 and in the CA1 region
of the hippocampus (Fig. 5A and 5D). Moderate to strong
labelling was observed in the stratum lacunosum-molecu-
lare (arrowheads in Fig. 5A and 5D), polymorphic layer of
the dentate gyrus (the hilus) (arrows in Fig. 4D,4E,4F and
in Fig. 5C and 5F), and molecular layer of the dentate
gyrus (the suprapyramidal blade) (arrowheads in Fig. 4C
and 4F and Fig. 5C and 5F). Cre-mediated recombination
was first detected in the dentate gyrus and gradually
spread to the terminal portion of CA3 (never the whole
extent of CA3), CA2 and CA1 regions of the hippocam-
pus. The pattern of recombination, assessed by β-galactos-
idase activity, in LV-Cre-EGFP injected mice was similar to
that produced by injection of AAV-Cre/AAV-GFP mixture.
Up to 3 weeks post injection, there were usually more cells
showing recombination following injection of AAV-Cre/
AAV-GFP mixture. To determine changes in the number of
neurons showing recombination, the number of β-galac-
tosidase-labelled cells in the hilar region of the dentate
gyrus was counted in 4–5 sections of brain at each time
point examined. At 3 days post injection 47 ± 9.3 (S.D.)
were labelled using AAV and 5 ± 8.9 using LV; at 7 days
post injection 68 ± 13.5 cells were labelled using AAV and
40 ± 5 using LV; at 2 weeks 83± 11.3 cells were labelled
using AAV and 50 ± 8.2 using LV; and at 4 weeks 214 ±
10.7 cells were labelled using AAV and 191 ± 28.8 using
LV. β-galactosidase was also observed in and around the
needle track after viral delivery of Cre (Fig. 5 arrows in A
and D). There were some scattered cells in the molecular
layer of the dentate gyrus (the suprapyramidal blade) and
the stratum lacunosum-moleculare. These were probably
interneurons, but one cannot exclude the possibility of
non-neuronal cells as well (arrowheads in Fig. 5B and 5E).
Injections of LV-Cre-EGFP and AAV-Cre/AAV-GFP mix-
ture viruses into neocortex and hippocampus also
resulted in recombination in glial cells, most obviously in
the white matter of the subcortical white matter and cor-
pus callosum (arrows in Fig. 5B and 5E) but the numbers
of labelled cells were much lower than the number of
nonneuronal cells in the same region which were GFP-
positive (compare Figs. 2 and 5).
Discussion
We have successfully used AAV and LV to deliver Cre
recombinase to a mammalian cell line in vitro and to cells
in the brains of Rosa26 mice 3 days to 4 weeks after stere-
otactic injection in the neocortex and hippocampus. The
AAV and LV vectors produced stable transduction of large
numbers of neural cells in the regions injected and pro-
duced recombination in those cells without obvious tis-
sue damage. These vectors can therefore be used to
inactivate genes in discrete regions of the adult
mammalian brain and offer exciting possibilities for stud-
ying gene function in the nervous system.
Our study extends the recently published studies, which
have shown that AAV, LV and adeno virus expressing Cre
protein can mediate loxP-dependent recombination
[17,25,26] and have potential to knock out the gene of
interest in the brain [27]. However, some studies have
reported inflammation, growth inhibition and toxic
effects of Cre in cultured cells and considerable tissue
damage following Cre delivery to the brain using viral vec-
tors [3,17,18]. In contrast, we observed the expression of
Cre in cultured 293T cells without obvious toxic effects.
We also found that Cre was expressed in mouse brain fol-
lowing injection of LV-Cre-EGFP, or a mixture of AAV-Cre
and AAV-GFP vectors, into neocortex and hippocampus
without any sign of cavity formation [cf [17]], in and
around the injection sites. In this respect our results more
Cre-mediated recombination following injection of LV-Cre-EGFP (A-C) and a ixture of AAV-Cre and AAV-GFP reco bin nt viruses (AAV-Cre/ AV-GFP mixture) (D-F) into th  eoco tex and hippocampus of Rosa26 portermi eFigure 4
Cre-mediated recombination following injection of LV-Cre-
EGFP (A-C) and a mixture of AAV-Cre and AAV-GFP 
recombinant viruses (AAV-Cre/AAV-GFP mixture) (D-F) 
into the neocortex and hippocampus of Rosa26 reporter 
mice. Expression of β-galactosidase, indicating Cre-mediated 
excision of the loxP flanked stop signal, was detected by the 
X-gal staining. β-galactosidase activity was prominent in the 
dentate gyrus of animals at all postinjection intervals (arrows 
in A-F). Scale bars A= 100 µm (applies also to B-F).Page 6 of 11
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BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/4Cre-mediated recombination in the neocortex and hippocampus of Rosa26 reporter mice, 4 weeks following injection of LV-EGFP recombinant virus (A-C) or a mixture of AAV-Cre and AAV-GFP recombinant virus s (AAV-Cre/AAV-GFP mix-tu ) (D-F)Figure 5
Cre-mediated recombination in the neocortex and hippocampus of Rosa26 reporter mice, 4 weeks following injection of LV-
Cre-EGFP recombinant virus (A-C) or a mixture of AAV-Cre and AAV-GFP recombinant viruses (AAV-Cre/AAV-GFP mix-
ture) (D-F). β-galactosidase activity is apparent in and around the needle track in the neocortex (arrows in A and D), in parts 
of the CA1, CA2 and terminal portion of the CA3 region of the hippocampus and in the dentate gyrus. Cells in stratum lacuno-
sum-moleculare (arrowheads in A and D), corpus callosum (arrow in B and E) were also observed. Parts of CA1 and CA2 from 
Fig. 5A and 5D are enlarged in Fig. 5B and 5E and the region of the dentate gyrus from Fig. 5A and 5D is enlarged in Fig. 5C and 
5F. Scale bars in A = 200 µm (applies also to D); B = 100 µm (applies also to C, E and F).Page 7 of 11
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the LV vector was injected in a much smaller total volume
(0.5 µl as opposed to 3 µl) than in the Pfeifer study [17]
but probably containing a similar number of viral parti-
cles (7.6 × 106 transgene expressing unit as opposed to 6 ×
107 infectious unit). It has been demonstrated that toxic
effects of Cre are dose dependent [18], and that low levels
of Cre expression can cause significant recombination
without having any adverse effects on cell viability in vitro
or in vivo [25,28]. It is possible that the levels of Cre
expression in the present study were sufficiently low to
avoid toxic effects observed by others [[3,17,18,29] see
above]. One of the advantages of Cre delivery to the CNS
with viral vectors is that expression of Cre can be restricted
to distinct groups of cells in the adult brain,
predominantly at the site of injection, and this may also
limit possible undesirable consequences of its expression.
The CMV promoter was chosen because of its ability to
drive expression of transgene expression in a variety of
cells [30,31] but the use of neuron- or glial-specific pro-
moters in viral vectors has the potential to further refine
the use of the Cre-loxP system in studies of gene expres-
sion in the CNS.
Both neuronal and glial cells were transduced by both
AAV and LV vectors, as shown by their expression of
immunohistochemically detectable Cre and GFP, but
neurons were the most abundant transduced cells with
both viral vectors. Transduction of glial cells was most
obvious in the subcortical white matter. AAV and LV vec-
tors using the CMV promoter have been reported to pro-
duce transgene expression predominantly in neurons but
to a lesser extent also in glia [9,26]. The reporter gene in
Rosa26 mice is also functional in all cell types. The stain-
ing pattern obtained by immunohistochemistry after LV-
Cre-EGFP and AAV-Cre/AAV-GFP mixture injections was
similar, suggesting that the specificity of infection was
similar. However the expression of Cre and GFP was to
some extent cell type specific. For example the neurons in
the dentate gyrus were more frequently transduced than
most other neurons in the hippocampal formation,
whereas neurons in most of the CA3 region (except the
terminal part) were only very rarely transduced. This
could simply reflect a difference in the ability of the
viruses to infect different types of neuron in the hippoc-
ampus, perhaps because of the presence of specific recep-
tors on the cell surface. If specific receptors for the viral
vectors determine which cells are infected, our results sug-
gest that similar receptors bind both vectors. It is possible
that the small volume of the vectors injected in our exper-
iments may have restricted the types of neurons infected.
Recombination, detected by β-galactosidase expression,
was found in the same populations of cells as expressed
GFP and/or Cre. Hence, recombination was predomi-
nantly in, but not restricted to, neurons and in the hippoc-
ampal formation recombination was most obvious in
dentate gyrus neurons and scarcely detectable in neurons
within most of CA3. β-galactosidase activity was detected
in dentate gyrus neurons 3 days after injection of LV-Cre-
EGFP and AAV-Cre/AAV-GFP mixture, although maximal
expression of β-galactosidase was found at 14 days or
more. AAV vectors carrying erythropoetin have been
reported to produce expression of the transgene in striated
muscle one day after infection [32] and lentiviral vectors
have been shown to produce GFP expression in retinal
pigment epithelium in 2–3 days [33] so that early expres-
sion of Cre would be expected using AAV-Cre. Kasper et al.
[25] using an AAV vector injected into forebrain have also
shown the increase of Cre activity over time. There was
some evidence that AAV-Cre was more efficient at produc-
ing recombination than LV-Cre in the first 3 weeks. Even
at 4 weeks after injection of either vector, fewer cells
showed recombination than expressed GFP, which sug-
gests that recombination was probably still occurring in
virally transduced cells in the brains of Rosa26 mice.
Conclusion
Our data show that Cre can be effectively delivered to dis-
crete regions of the adult mammalian brain using AAV
and LV vectors. This offers the potential for producing
changes in the genome of neurons in discrete regions of
the brain at the time of choice. The limiting factor in
exploiting this technology is likely to be the generation of
strains of mice with loxP-flanked genes of interest to
neuroscience.
Methods
The AAV vector pTRCGW (5.6 kb), (a kind gift from Paul
Dijkhuizen, The Netherlands Institute for Brain Research,
Amsterdam, The Netherlands), carrying the ampicillin
resistance gene, inverted terminal repeats (ITR), human
immediate early cytomegalovirus promoter (CMV), wood
chuck posttranscriptional regulatory element (WPRE) and
multiple restriction sites, was used to construct the rAAV-
Cre vector plasmid. The 1.1 Kb fragment of Cre gene along
with the nuclear localization signal (NLS) was excised
from pNSE-Cre [2] by digesting with Hind III and NdeI
restriction enzymes and blunted on both sites using Ecoli
DNA polymerase I (klenow fragment). AAV-Cre was cre-
ated by inserting NLS-Cre between two ITRs in pTRCGW
vector that had been digested with Spe1 and Bam H1 sites,
were also blunt ended by using klenow fragment.
To generate the LV-Cre-EGFP plasmid, a 2 Kb NotI/BglII
fragment containing Cre-EGFP was isolated from pCMV-
Cre-EGFP, blunted, and ligated into the multiple cloning
site of the lentiviral transfer vector p156RRLsin-PPTh-
CMV-GFP-pre [6,34,35]. This vector contains a CMV pro-
moter along with the HIV-1-Sin 18 LTR and the HIV-1Page 8 of 11
(page number not for citation purposes)
BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/4genomic RNA packaging signal. pCMV-Cre-EGFP was cre-
ated by inserting NLS-Cre derived from pJTCRE3 [35] into
the multiple cloning site of pEGFP-N3 (Clontech, CA,
USA).
AAV-Cre Viral vector production
Ten culture dishes (100-mm diameter), each containing 5
× 106 293T cells, were co-transfected by calcium phos-
phate with 5 µg of either AAV-GFP or AAV-Cre vector plas-
mid and 15 µg of the packaging plasmid(PDG) [37]
Twelve-fourteen hrs following the transfection, medium
was replaced by complete Dulbecco's Modified Eagle's
Medium (DMEM, Gibco) containing 10% FCS (Gibco)
and 1% of a mixture of penicillin (100 lU/ml) and strep-
tomycin (100 pg/ml), in which the cells were incubated
for 48 hrs at 37°C and 5% CO2. The cells were dislodged
from the culture dishes in 2 ml of PBS, pH 7.5, 1 mM
MgCl2 and 10 mg/ml DNase I and freeze-thawed three
times in a dry ice/100% ethanol bath and 37°C water
bath. The cell debris was spun down at 4000 rpm for 20
min at 4°C. The supernatant was passed through a
heparin-agarose beads column (H-6508 Sigma, Econo
column, BioRad CA, USA) followed by Iodixanol purifica-
tion (Nycomed Pharma AS, Oslo, Norway) and centricon
concentrator (Amicon, USA) as described previously [38].
The transgene expressing unit titre (tu/ml) was deter-
mined by co-infection of 293T cells with serial dilutions
(10-2, 10-3, 10-4, 10-5 and 10-6) of the AAV-GFP or AAV-Cre
viral vector stock in the presence of adenovirus
(multiplicity of infection, MOI = 3). The titre of AAV-GFP
was determined by counting GFP positive cells in a fluo-
rescence microscope following 16 hrs infection. For detec-
tion of AAV-Cre, cells were washed with PBS, fixed with
4% PFA and processed for the immunohistochemical
detection of Cre as described below. The titre was found
to be 1 × 108 tu/ml for both AAV-GFP and AAV-Cre.
To determine if Cre was expressed in AAV-Cre infected
cells in vitro, 293T cells were plated in 6 well plates (5 ×
105 per well) in complete DMEM. Cells were infected with
AAV-Cre (1:10,000) in the presence of adenovirus (MOI =
3). Fourteen-forty eight hrs following the infection, cells
were washed with PBS and fixed with 4% PFA for 15 min,
followed by washing with PBS (3 × 10 min). Cells were
then incubated with antibody to Cre (1:200, Berkeley, CA,
USA), diluted in 50 mM Tris-HCl, pH 7.5, 0.5 M NaCl and
0.1% Triton) overnight at 4°C. The following morning,
cells were washed with PBS (3 × 5 min) and incubated
with ABC solution (Avidin Biotin Complex, Vector labo-
ratories, CA USA) for an hour at room temperature. The
cells were washed with PBS (3 × 5 min) and allowed to
react for 5 min in a solution of 0.05% diamino benzidine
and 0.03% hydrogen peroxide in PBS. The cells were
washed with PBS to terminate the reaction and subse-
quently observed under a bright-field microscope (Zeiss
Axiovert 10).
LV-Cre-EGFP viral vector production
For viral vector production, the LV-Cre-EGFP transfer plas-
mid was co-transfected together with the viral core pack-
aging construct pCMVdeltaR8.74 and the VSV-G envelope
protein vector pMD.G.2 into 293T cells as previously
described[39]. The original transfer vector and the helper
plasmids were obtained from Dr. L. Naldini (Institute for
Cancer Research, University of Torino, Italy). Briefly, 5 ×
106 293T cells were seeded in 10 cm dishes 24 hrs prior to
transfection in complete Iscove's Modified Dulbecco's
Medium (IMDM) containing 10% FCS, glutamine and
1% penicillin/streptomycin in a 5% CO2 incubator, the
culture medium was changed 2 hrs prior to transfection.
Ten µg of transfer vector plasmid, 6.5 µg envelope plas-
mid, and 3.5 µg of packaging plasmid were co-transfected
using the calcium phosphate method. The medium was
replaced after 14–16 hrs and the conditioned medium
was collected 24 hrs later, cleared by low-speed centrifu-
gation (1000 rpm for 5 minutes) and filtered through
0.22 µm cellulose acetate filters. The supernatant was con-
centrated about 100 fold by ultra centrifugation (20,000
rpm for 2.5 hrs). The pellet was re-suspended in PBS and
virus was aliquoted and stored at -80°C. The titre was
determined by infecting 293T cells with serial dilution of
the LV-Cre-EGFP virus (10-3, 10-4, 10-5 and 10-6) in com-
plete IMDM. Cells were incubated for 16 hrs and the
medium was replaced with fresh IMDM and cells were
incubated for 24 hrs. The titre was determined by count-
ing GFP positive cells under a fluorescence microscope.
This was confirmed by counting positive cells after Cre-
immunocytochemistry as described above. The titre of the
first stock was 1.5 × 1010 tu/ml and the second stock was
found to be 2 × 109.
To determine if Cre was expressed in LV-Cre-EGFP
infected cells in vitro, 293T cells (5 × 105 per well) were
plated in complete IMDM. The next day, cells were
infected with LV-Cre-EGFP (1:10,000) in complete IMDM
medium for 16 hrs, medium was replaced with fresh
medium and incubated for 24–48 hrs. These experiments
were replicated 3 times. For immunofluorescence label-
ling, cells were washed with PBS and fixed with 4% para-
formaldehyde for 15 min. followed by washing with PBS
(3 × 10 min). Cells were then incubated with the Cre anti-
body (1:200, diluted in 50 mM Tris-HCl, pH 7.5, 0.5 M
NaCl and 0.1% Triton) overnight at 4°C. Next morning
cells were washed with PBS (3 × 10 min) and incubated
with Cy3-conjugated goat anti-mouse (1:400, Jackson
laboratories PA, USA) for an hour at room temperature.
Cells were washed with PBS (3 × 10 min), mounted on
slides and observed under a confocal microscope (LSMPage 9 of 11
(page number not for citation purposes)
BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/4410 Zeiss) using 488 nm and 543 nm excitations for GFP
and Cy3 respectively.
AAV and LV delivery of Cre into the brain
Rosa26 reporter mice (22–30 g) were deeply anaesthe-
tised by a fluanisone /fentanyl mixture containing Hyp-
norm (Janssen Pharmaceutical, UK) and Dormicum
(Roche, NL) and water in a ratio of 1:1:2 (10 µl/gm I.P.).
Virus was injected into the cortex and hippocampus via
30G stainless needle attached by polyethylene tubing to a
10-µl Hamilton syringe and a Harvard 22 microinjection
pump. 0.8 µl of a mixture of AAV-Cre and AAV-GFP (AAV-
Cre/AAV-GFP mixture, 9:1) or 0.5 µl LV-Cre-EGFP virus
was injected into the cortex (anterioposterior -2, lateral +
1.3, dorsoventral -0.45) and hippocampus (anterioposte-
rior -2, lateral + 1.3, dorsoventral -1.55) [40] at a rate of
0.2 µl/min. The needle remained in place for an
additional 5 minutes to facilitate the controlled delivery
of virus. Three days and 1, 2 and 4 weeks following the
injections mice were perfused with 4% PFA. Four mice
were examined for each time point. Sections of the brain
were cut in the coronal plane at a thickness of 50 µm with
a vibratome and processed for β-galactosidase enzyme
histochemical, immunohistochemical, and double
immunofluorescence studies.
β-galactosidase staining was done by incubating the sec-
tions for an hour at 37°C with X-gal-solution containing
5 mMK4Fe(CN)6, 5 mM K3Fe(CN)6, 2 mM MgCl2, 1 mg/
ml 5-bromo-4-chloro-3-indolyl-D-galactoside in PBS. The
X-gal reacted sections were washed with PBS (3 × 10 min),
dehydrated and embedded in entellan mounting
medium. Immunohistochemistry for GFP was carried out
by the ABC method using diamino-benzidine as a sub-
strate [41], and with rabbit anti GFP (1:100, Chemicon,
CA, USA) as primary antibody and biotinylated anti-rab-
bit (1:200, Vector) as secondary antibody.
Colocalization of Cre and GFP was examined by using a
double immunofluorescence. A mixture of biotin labelled
monoclonal Cre antibody (1:1000) and polyclonal GFP
antibody (1:100) was used as primary antibodies, while a
mixture of streptavidin-conjugated horseradish peroxi-
dase (1:200, Life Sciences, MA, USA) and FITC conjugated
anti-rabbit (1:100, Sigma) was used as secondary antibod-
ies. Cre signal was enhanced by incubating the sections in
fluorophore labelled tyramide solution (1:200, Life Sci-
ences) for 30 min at RT, mounted sections were analyzed
by fluorescence microscope fitted with SP confocal head
(Leica DMRE) using Leica confocal software.
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